Evidence-based clinical review
Outpatient Community-Acquired Pneumonia in 2026: Are We Still Treating Too Broadly?
Abstract
Background
Outpatient community-acquired pneumonia (CAP) is a common setting for antibiotic overuse, but prescribing too broadly is not a single isolated error. Excess treatment can begin with prescribing for an uncertain or viral diagnosis, continue with unnecessary spectrum coverage, and end with a course that persists long after clinical stability. The 2026 American Thoracic Society (ATS) guideline update changes the discussion around treatment duration and adds conditional recommendations for adults with CAP who test positive for a respiratory virus. Meanwhile, the 2019 ATS and Infectious Diseases Society of America (IDSA) guideline remains the primary U.S. source for specific outpatient empiric regimens. [1,2]
Objective
This review provides a clinician-facing framework for deciding whether an outpatient with suspected CAP actually needs antibacterial therapy, determining how broad the initial therapy should be, and identifying when treatment can safely stop.
Key Findings
The 2026 ATS update suggests withholding empiric antibacterials in virus-positive outpatients without comorbidities, but it suggests using antibiotics in virus-positive outpatients who have comorbidities. The IDSA publicly disagreed with the latter recommendation, favoring an individualized and dynamic assessment because the direct evidence remains very limited. [1,3] Historical U.S. claims data through 2019 show that unnecessary broad-spectrum prescribing in otherwise healthy adults declined but remained common, proving the problem is credible even though a current national 2026 rate is unavailable. [4] In a separate observational cohort of otherwise healthy adults, broad-spectrum regimens were associated with more adverse drug events than narrow-spectrum comparators, although residual confounding and outcome misclassification remain possible. [5] Furthermore, narrow therapy does not automatically mean routine azithromycin monotherapy, because available U.S. pneumococcal surveillance found macrolide resistance well above the guideline threshold of 25% in most regions. [2,6]
Conclusion
Outpatient CAP remains highly vulnerable to overly broad treatment, but the corrective strategy is not reflexive narrowing. The ultimate goal is to select the least broad regimen that remains clinically adequate for the patient’s diagnostic certainty, comorbidity profile, resistant-pathogen risk, illness severity, drug-specific hazards, and follow-up reliability.
Introduction
Scope of This Review and Excluded Populations
This review specifically addresses immunocompetent adults with suspected or confirmed CAP who are being considered for outpatient management in the United States. It does not provide primary regimens for children, patients with substantial immunocompromise, hospital-acquired or ventilator-associated pneumonia, severe CAP requiring hospital admission, pregnancy-specific decision-making, or pneumonia caused by unusual travel, occupational, or endemic fungal exposures. [1,2]
Are We Still Overprescribing? The Historical Data and Current Reality
The strongest stewardship argument in 2026 is not that broad-spectrum antibiotics are inherently inappropriate. Rather, it is that broader spectrum coverage should be earned by a documented risk profile. Otherwise healthy adults without risk factors for methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa generally have guideline-supported oral options that avoid routine fluoroquinolone exposure and unnecessary combination therapy. Adults with specified comorbidities have a broader guideline framework because their outcome risk and probability of encountering less susceptible pathogens are inherently higher. [2]
Historical utilization data strongly support the concern behind this premise. In a MarketScan cohort covering 2008 through 2019, 35% of otherwise healthy outpatient CAP episodes received broad-spectrum regimens that were not recommended for that specific group under the 2007 guideline framework. Annual broad-spectrum use in that healthy group fell from 45% to 19%, but it certainly did not disappear. These figures describe commercially insured adults aged 18 to 64 years and should not be presented as the definitive national prescribing rate in 2026. [4]
Identifying Where Prescribing Becomes Unnecessarily Broad
Treating a patient too broadly can occur at three distinct points in the clinical encounter.
Point 1: Treating an Incorrect or Unconfirmed Diagnosis
Community-acquired pneumonia should never be reduced to a simple cough plus an antibiotic prescription. The 2019 guideline’s evidence base defines CAP using compatible clinical features plus radiographic confirmation, primarily because symptoms and physical examination findings alone are highly inaccurate. Chest radiography remains the usual standard of care. The 2026 ATS update allows lung ultrasound as an alternative where appropriate expertise is available, but successful implementation depends heavily on operator skill and local clinical workflow. [1,2]
Additionally, an initial procalcitonin result should not be used as the sole reason to withhold antibiotics when clinically suspected and radiographically confirmed CAP is present. Conversely, a low biomarker value does not magically convert an uncertain respiratory syndrome into bacterial pneumonia. The test must always remain subordinate to the complete diagnostic assessment. [2]
Point 2: Selecting a Broader Spectrum Than the Risk Profile Requires
For an otherwise healthy adult without the guideline’s listed comorbidities or resistant-pathogen risk factors, high-dose amoxicillin or doxycycline is usually the most appropriate starting framework. Macrolide monotherapy is strictly conditional on local pneumococcal resistance being below 25%, a threshold that is simply not met in most available U.S. surveillance regions. [2,6]
For adults with chronic heart, lung, liver, or renal disease, diabetes mellitus, alcoholism, malignancy, or asplenia, the 2019 guideline recommends either a beta-lactam plus a macrolide or doxycycline, or respiratory fluoroquinolone monotherapy. However, that recommendation does not eliminate the need for patient-level judgment. The number, severity, and control of comorbidities, along with allergy history, recent antibiotic exposure, arrhythmia risk, prior Clostridioides difficile infection, renal function, drug interactions, and follow-up reliability, should all heavily influence the final choice. [2]
Point 3: Continuing Antibiotics After the Patient Has Stabilized
The 2026 ATS update conditionally suggests fewer than 5 days of antibiotics for selected adult outpatients who have reached clinical stability, with a minimum of 3 effective treatment days. This is not a universal 3-day prescription. It requires an effective agent, a favorable clinical trajectory, and the absence of any complicating feature that makes early discontinuation unsafe. [1]
Confirming That Outpatient Management Is Clinically Appropriate
The decision about antibiotic spectrum must follow the decision about the clinical setting. The 2019 guideline recommends using a validated prognostic tool, preferentially the Pneumonia Severity Index, alongside clinical judgment. A low score does not override hypoxemia, hemodynamic instability, an inability to take oral medication, decompensated comorbidity, cognitive or functional limitations, or an unsafe home and follow-up plan. [2]
Immediate emergency evaluation or hospital-level assessment is entirely appropriate when there is worsening hypoxemia, hypotension, new confusion, marked work of breathing, an inability to maintain hydration or oral therapy, rapidly progressive illness, concern for sepsis, or failure of outpatient management. These patients fall completely outside a routine narrow versus broad office prescribing decision. [1,2]
Navigating the 2026 Controversy Over Positive Viral Testing
A positive respiratory viral assay certainly reduces the probability that bacteria are driving the illness, but it does not perfectly exclude bacterial coinfection. No available combination of symptoms, imaging, and routine laboratory tests reliably distinguishes viral pneumonia from bacterial coinfection in every single patient. [1]
The 2026 ATS recommendations for adults with clinical and imaging-confirmed CAP are conditional and based on very low-quality evidence:
| Outpatient group with a positive respiratory viral test | ATS 2026 position | Practical interpretation |
| No relevant comorbidity | Suggest no empiric antibacterial therapy | Reasonable when severity is low, bacterial features are weak, follow-up is reliable, and the patient is not deteriorating. [1] |
| One or more relevant comorbidities | Suggest empiric antibacterial therapy | Do not treat comorbidity as an automatic mandate. Consider the burden and control of the comorbidity, illness severity, bacterial features, prior antibiotic harms, and follow-up reliability. [1] |
| Comorbid outpatient under the IDSA position statement | IDSA did not endorse the routine-antibiotic recommendation | The IDSA favors individualized, dynamic decisions that account for the clinical trajectory, severity, and specific evidence for or against coinfection. [3] |
This disagreement matters significantly because the ATS evidence review found no eligible direct comparative study that definitively answered the outpatient virus-positive question. For a stable patient with a single well-controlled comorbidity, convincing viral features, low clinical concern for bacterial coinfection, and reliable follow-up, withholding or stopping antibiotics may be entirely reasonable after an individualized assessment. For an older or frail patient with multiple or poorly controlled comorbidities, focal consolidation, purulent sputum, a biphasic “double-sickening” course, rising inflammatory markers, or worsening physiology, empiric antibacterial treatment becomes much easier to justify. [1,3]
Selecting Empiric Outpatient Regimens Using the 2019 Framework
The 2026 ATS document is a focused update, not a complete replacement for the 2019 outpatient antibiotic table. The following doses are selected guideline options for adults with normal organ function. They are not a substitute for current prescribing information, a local antibiogram, allergy assessment, interaction screening, renal or hepatic adjustment, or pregnancy-specific review. [1,2]
| Patient group | Guideline-listed initial options | Stewardship notes |
| Healthy adult without listed comorbidity or MRSA/P. aeruginosa risk factor | Amoxicillin 1 g orally three times daily; or doxycycline 100 mg orally twice daily | These are the principal narrow-spectrum options in the 2019 U.S. guideline. [2] |
| Same group, only where local pneumococcal macrolide resistance is below 25% | Azithromycin 500 mg on day 1, then 250 mg daily; or clarithromycin 500 mg twice daily or extended-release 1,000 mg daily | Do not assume a standard azithromycin pack is the narrow default. Verify local resistance and QT or interaction risk. [2,6] |
| Comorbid adult: combination approach | Amoxicillin/clavulanate 500/125 mg three times daily, 875/125 mg twice daily, or extended-release 2,000/125 mg twice daily; or cefpodoxime 200 mg twice daily; or cefuroxime 500 mg twice daily; plus azithromycin, clarithromycin, or doxycycline at the doses above | Combination therapy broadens coverage. Confirm that the comorbidity and patient-specific risk truly justify the added exposure. [2] |
| Comorbid adult: monotherapy alternative | Levofloxacin 750 mg once daily or moxifloxacin 400 mg once daily | Respiratory fluoroquinolones are guideline-listed options, not mandatory default therapy. Weigh patient-specific safety, interaction, and renal risks before selecting one. [2] |
Dosing note: The guideline-listed amoxicillin dose of 1 g three times daily is higher than the usual lower-respiratory adult dosing shown in the reviewed generic amoxicillin label, which lists 875 mg every 12 hours or 500 mg every 8 hours. Treat 1 g three times daily as guideline-directed CAP dosing rather than a direct transcription of the reviewed product label, and always verify current labeling and renal function before prescribing. [2,7]
Distinguishing Resistant-Pathogen Risk From Ordinary Comorbidities
The 2019 guideline identifies prior respiratory isolation of MRSA or P. aeruginosa, or recent hospitalization with parenteral antibiotics within the previous 90 days, as key risk factors for these specific pathogens. Routine outpatient addition of anti-MRSA or antipseudomonal therapy without validated risk is not recommended. When such risk is credible, the patient may need a sputum culture, a broader diagnostic workup, local infectious diseases guidance, or hospital-level evaluation rather than an improvised office regimen. [2]
Recent oral antibiotic exposure also matters, even when it does not meet the formal MRSA or P. aeruginosa criteria. It may alter resistance probability and should discourage repeating the same antibiotic class without a clear clinical reason. Local antibiograms and prior patient-specific microbiology are far more informative than national averages. [2,6]
Why Azithromycin Monotherapy Is Rarely the Answer to Overprescribing
The 2019 guideline intentionally moved away from routine macrolide monotherapy because of treatment failures with macrolide-resistant pneumococci and high U.S. resistance rates. In a 2018 through 2019 multicenter analysis of 3,626 nonduplicate adult S. pneumoniae isolates from 329 U.S. facilities, 39.5% were macrolide-resistant overall, and 47.3% of respiratory isolates were resistant. Most regions easily exceeded the 25% threshold. These data are not a substitute for a 2026 local antibiogram, but they make empiric macrolide monotherapy very difficult to defend without documented local susceptibility. [2,6]
Doxycycline and high-dose amoxicillin successfully avoid routine fluoroquinolone exposure, but neither is universally correct for every patient. They differ significantly in spectrum, allergy considerations, drug interactions, tolerability, and organ-function requirements. The least broad adequate option is always highly patient-specific. [2,7]
Implementing Shorter Antibiotic Courses Based on 2026 Updates
The 2026 ATS update suggests a course shorter than 5 days for selected stable outpatients, requiring at least 3 effective days of treatment. Clinical stability includes improvement toward normal temperature, heart rate below 100 beats per minute, respiratory rate below 24 breaths per minute, systolic blood pressure at least 90 mm Hg, oxygen saturation at least 90% or a return to baseline oxygen requirement, and normal mental status. [1]
Short-course treatment is far less attractive when follow-up is unreliable, the initial agent was inactive, the patient has not yet achieved stability, or there is suspected S. aureus, P. aeruginosa, Legionella, another intracellular pathogen, necrotizing disease, dense or multilobar consolidation, bronchiectasis, postobstructive pneumonia, chronic respiratory insufficiency, recent hospitalization, or long-term care exposure. [1]
This new recommendation should change the clinical default from finishing 7 or 10 days simply because that is what was originally prescribed, to setting an early stop target and extending therapy only when the clinical course or specific pathogen warrants it. It does not make every product-labeled regimen perfectly interchangeable. For example, reviewed levofloxacin labeling includes a 750 mg once-daily 5-day CAP regimen, while the ATS duration recommendation is an evidence-based, patient-selection recommendation. Clinicians must reconcile guideline duration, drug labeling, the specific organism, clinical response, and patient factors rather than applying a single number mechanically. [1,8]
Failure to reach clinical stability should immediately prompt diagnostic reconsideration. Possibilities include an incorrect diagnosis, a resistant or uncovered pathogen, empyema, lung abscess, airway obstruction, pulmonary embolism, heart failure, malignancy, or another inflammatory process. Automatic extension or broadening of therapy without careful reassessment can easily compound the original clinical error. [1,2]
Weighing Adverse Drug Events in the Spectrum Decision
In a claims-based cohort of 145,137 otherwise healthy, commercially insured adults aged 18 to 64 years treated for outpatient CAP from 2007 through 2019, broad-spectrum regimens were associated with an increased risk of several adverse drug events compared with macrolide monotherapy. Beta-lactam regimens were associated with more gastrointestinal events, non-C. difficile diarrhea, and vulvovaginal candidiasis. Fluoroquinolones were associated with more selected gastrointestinal and allergy outcomes. The study was observational, outpatient CAP coding was not independently validated, adherence was unknown, and amoxicillin monotherapy was too uncommon for robust statistical estimates. Therefore, the findings strongly support stewardship but do not definitively prove that one specific regimen is safest for every single patient. [5]
Levofloxacin labeling carries a prominent boxed warning for disabling and potentially irreversible serious reactions that include tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis. The label also addresses aortic aneurysm or dissection risk, QT prolongation, dysglycemia, and C. difficile-associated diarrhea. These hazards do not strictly prohibit fluoroquinolone use for CAP, but they certainly raise the threshold for choosing one when a safer and equally adequate regimen is available. [8]
Broader combination therapy also increases pill burden, interaction opportunities, gastrointestinal toxicity, and microbial selection pressure. The relevant clinical comparison is not simply broad drug versus narrow drug. It is the expected benefit of added coverage versus the incremental harm for this particular patient. [2,5,8]
A Practical Six-Step Framework for Outpatient Prescribing
Step 1: Confirm the Clinical Syndrome Require a coherent clinical syndrome and objective imaging whenever feasible. Reconsider bronchitis, viral upper respiratory infection, asthma or COPD exacerbation, heart failure, pulmonary embolism, malignancy, and other common mimics before officially labeling the illness as CAP. [1,2]
Step 2: Confirm That Outpatient Care Is Safe Use the Pneumonia Severity Index plus sound clinical judgment. Carefully evaluate oxygenation, blood pressure, mental status, oral intake, comorbidity decompensation, functional status, and the reliability of outpatient follow-up. [2]
Step 3: Decide Whether Any Antibacterial Is Actually Needed A positive viral test in a stable outpatient without comorbidity supports withholding empiric antibiotics under the conditional ATS recommendation. In comorbid outpatients, acknowledge the ATS and IDSA disagreement and make a highly individualized decision rather than treating the medical problem list as an automatic antibiotic trigger. [1,3]
Step 4: Choose the Least Broad Adequate Regimen For otherwise healthy adults, start with amoxicillin or doxycycline unless a specific contraindication or resistance concern points elsewhere. Use macrolide monotherapy only when local pneumococcal resistance is confirmed to be below 25%. For guideline-listed comorbidities, select combination therapy or a respiratory fluoroquinolone only after carefully weighing the added coverage against drug-specific harm. [2,6,8]
Step 5: Write the Stop Plan at the Very Start For selected patients, plan for fewer than 5 days of therapy with at least 3 effective days, entirely contingent on achieving clinical stability. Explicitly document what clinical features would require continuation, a different agent, additional testing, or escalation of care. [1]
Step 6: Reassess Nonresponse Instead of Reflexively Broadening If clinical stability is not emerging, revisit the diagnosis, clinical setting, medication adherence, microbiology, potential complications, and source control. Broadening therapy without a revised clinical hypothesis is not stewardship, and it may severely delay the recognition of a noninfectious diagnosis. [1,2]
Special Populations and Situations Requiring Alternative Pathways
The standard regimen table should never be applied without modification to pregnancy, substantial immunocompromise, advanced renal or hepatic dysfunction, severe beta-lactam allergy, prolonged QT risk, myasthenia gravis, structural lung disease with prior resistant gram-negative isolates, recent foreign travel, endemic mycosis exposure, or suspected aspiration with abscess or empyema. These complex situations require targeted guideline review, label verification, microbiology consultation, and sometimes specialist involvement. [1,2,7,8]
Older adults also deserve much more than a simple checkbox approach. Frailty, cognitive impairment, aspiration risk, polypharmacy, baseline oxygen use, renal reserve, and the ability to recognize clinical deterioration may matter far more than a single chronological-age threshold. [1,2]
Acknowledging Evidence Limitations and Priorities for Future Research
The 2026 ATS recommendations regarding virus-positive outpatients are based on indirect and very low-quality evidence, and the IDSA’s formal nonendorsement underscores a genuine professional disagreement. The short-course outpatient recommendation is similarly conditional and supported by low-quality evidence, with several important clinical exclusions. [1,3]
Furthermore, the utilization and safety studies rely on claims data through 2019, meaning they cannot quantify present-day 2026 prescribing habits or fully establish causal differences among specific regimens. Macrolide resistance surveillance is also historical and should never replace current local data. [4-6]
High-value next steps for the medical community include pragmatic outpatient trials of antibiotic withholding after positive viral testing, trials stratified by comorbidity burden rather than a binary comorbidity label, comparative effectiveness studies of high-dose amoxicillin and doxycycline, and better integration of local resistance and patient-specific microbiology into electronic prescribing systems. [1,4-6]
Many adults with outpatient CAP remain vulnerable to treatment that is simply too broad, but the problem extends far beyond fluoroquinolone use alone. True stewardship begins by confirming pneumonia, separating the need for bacterial treatment from spectrum selection, and setting a stability-based stop plan. In otherwise healthy adults, amoxicillin or doxycycline often provides a highly adequate initial framework. Broader combination therapy or respiratory fluoroquinolone monotherapy remains entirely reasonable when comorbidity, resistance risk, illness severity, allergy history, or follow-up reliability justifies it. [1,2]
The 2026 guideline framework points clearly toward more deliberate treatment. This means fewer automatic antibiotics after a viral result, fewer automatic broad regimens in low-risk adults, and fewer automatic 5 to 10-day courses after clinical stability is achieved. The safest prescription is not always the narrowest one available, but it should always be the narrowest one that remains clinically adequate for the individual patient. [1-6]
Clinical Update Disclaimer
This article reflects literature, professional guidance, and prescribing information reviewed through August 19, 2026. Guidelines, regulatory labeling, safety information, local resistance patterns, and clinical evidence may change. Clinicians should confirm current authoritative guidance, product labeling, local antibiograms, renal and hepatic dosing, allergy and interaction information, and patient-specific circumstances before applying this material.
References
- Jones BE, Ramirez JA, Oren E, Soni NJ, Sullivan LR, Restrepo MI, et al. Diagnosis and Management of Community-acquired Pneumonia: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2026;212(1):24-44. DOI. PubMed. PMID: 40679934.
- Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. DOI. PubMed. PMID: 31573350; PMCID: PMC6812437.
- Klompas M, Al-Hasan MN, Al Mohajer M, Colgrove R, Doron S, File TM Jr, et al. Infectious Diseases Society of America Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update. Clin Infect Dis. 2026;82(4):622-624. DOI. PubMed. PMID: 41340493.
- Nickel KB, Durkin MJ, Olsen MA, Sahrmann JM, Neuner E, O’Neil CA, Butler AM, CDC Prevention Epicenters Program. Utilization of broad- versus narrow-spectrum antibiotics for the treatment of outpatient community-acquired pneumonia among adults in the United States. Pharmacoepidemiol Drug Saf. 2024;33(4):e5779. DOI. PubMed. PMID: 38511244; PMCID: PMC11016291.
- Butler AM, Nickel KB, Olsen MA, Sahrmann JM, Colvin R, Neuner E, O’Neil CA, Fraser VJ, Durkin MJ, CDC Prevention Epicenters Program. Comparative Safety of Different Antibiotic Regimens for the Treatment of Outpatient Community-Acquired Pneumonia Among Otherwise Healthy Adults. Clin Infect Dis. 2025;81(6):1141-1151. DOI. PubMed. PMID: 39442057; PMCID: PMC12355227.
- Gupta V, Yu KC, Schranz J, Gelone SP. A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-Resistant Streptococcus pneumoniae in Ambulatory and Hospitalized Adult Patients in the United States. Open Forum Infect Dis. 2021;8(7):ofab063. DOI. PubMed. PMID: 34250183; PMCID: PMC8266646.
- DailyMed. Amoxicillin capsule: prescribing information. National Library of Medicine. Official label. Accessed August 19, 2026.
- DailyMed. Levofloxacin tablet: prescribing information. National Library of Medicine. Official label. Accessed August 19, 2026.
Recent Articles
Integrative Perspectives on Cognition, Emotion, and Digital Behavior
Sleep-related:
Longevity/Nutrition & Diet:
Philosophical / Happiness / Social:
Other:
Modern Mind Unveiled
Developed under the direction of David McAuley, Pharm.D., this collection explores what it means to think, feel, and connect in the modern world. Drawing upon decades of clinical experience and digital innovation, Dr. McAuley and the GlobalRPh initiative translate complex scientific ideas into clear, usable insights for clinicians, educators, and students.
The series investigates essential themes–cognitive bias, emotional regulation, digital attention, and meaning-making—revealing how the modern mind adapts to information overload, uncertainty, and constant stimulation.
At its core, the project reflects GlobalRPh’s commitment to advancing evidence-based medical education and clinical decision support. Yet it also moves beyond pharmacotherapy, examining the psychological and behavioral dimensions that shape how healthcare professionals think, learn, and lead.
Through a synthesis of empirical research and philosophical reflection, Modern Mind Unveiled deepens our understanding of both the strengths and vulnerabilities of the human mind. It invites readers to see medicine not merely as a science of intervention, but as a discipline of perception, empathy, and awareness–an approach essential for thoughtful practice in the 21st century.
The Six Core Themes
I. Human Behavior and Cognitive Patterns
Examining the often-unconscious mechanisms that guide human choice-how we navigate uncertainty, balance logic with intuition, and adapt through seemingly irrational behavior.
II. Emotion, Relationships, and Social Dynamics
Investigating the structure of empathy, the psychology of belonging, and the influence of abundance and selectivity on modern social connection.
III. Technology, Media, and the Digital Mind
Analyzing how digital environments reshape cognition, attention, and identity- exploring ideas such as gamification, information overload, and cognitive “nutrition” in online spaces.
IV. Cognitive Bias, Memory, and Decision Architecture
Exploring how memory, prediction, and self-awareness interact in decision-making, and how external systems increasingly serve as extensions of thought.
V. Habits, Health, and Psychological Resilience
Understanding how habits sustain or erode well-being-considering anhedonia, creative rest, and the restoration of mental balance in demanding professional and personal contexts.
VI. Philosophy, Meaning, and the Self
Reflecting on continuity of identity, the pursuit of coherence, and the construction of meaning amid existential and informational noise.
Keywords
Cognitive Science • Behavioral Psychology • Digital Media • Emotional Regulation • Attention • Decision-Making • Empathy • Memory • Bias • Mental Health • Technology and Identity • Human Behavior • Meaning-Making • Social Connection • Modern Mind
Video Section
